A Problem in NIH and Federally Funded Prostate Cancer Interventional Clinical Trials

• Published in: Journal of racial and ethnic health disparities 2024-10, Vol.11 (5), p.2740-2755
• Main Authors: Sultan, Dawood H., Ghebrezadik, Diana G., Smith, Desiree S., Ombengi, David N., Ayedun, Lolade, Luke, Faith E., Demery, Janee L., Scoggins, Chris T., Penn-Marshall, Michelle
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; African Americans; Androgens; Biomarkers; Biopsy; Black or African American - statistics & numerical data; Body weight loss; Clinical medicine; Clinical research; Clinical trials; Clinical Trials as Topic; Comorbidity; Control methods; Coping; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - therapy; Diet; Drug therapy; Drugs; Epidemiology; Ethnicity; Financing, Government; Funding; Humans; Incontinence; Intervention; Male; Males; Medical procedures; Medical prognosis; Medicine; Medicine & Public Health; Men; Metastasis; Middle Aged; Mortality; National Institutes of Health (U.S.); National libraries; Obesity; Obesity - epidemiology; Optimization; Patients; Prostate; Prostate cancer; Prostatic Neoplasms - ethnology; Prostatic Neoplasms - therapy; Quality of Life Research; Recurrence; Research funding; Risk factors; Social Inequality; Social Structure; Survival; Testosterone; Treatment preferences; Type 2 diabetes mellitus; Ultrasonic imaging; United States; Vaccines; Weight loss; White People - statistics & numerical data; Young Adult
• ISSN: 2197-3792; 2196-8837; 2196-8837
• DOI: 10.1007/s40615-023-01737-9

Background Obesity, diagnosed in 41.1% of African American (AA) men, is a risk factor for prostate cancer (PCa) recurrence, progression, and increased mortality. Obesity is associated with aggressive PCa only in AA men and not White American (WA) men. The overall health of AA PCa patients is also more likely to be adversely affected by comorbid type 2 diabetes (T2D), often an outcome of obesity and a cause of reduced odds of PCa survival. This evidence suggests that preventing and controlling comorbid obesity and T2D in AA men diagnosed with PCa should be a research funding priority. Aim The aim of this study is to determine if federally funded PCa clinical trials controlled T2D and obesity. Methods Completed interventional PCa clinical trials conducted in the USA, funded by the NIH or other federal agency, which included males aged 18–64 years, and reported study protocols were included in the study. We examined the intervention modalities used in the trials to determine if any attempted to control obesity and T2D. Results Fifty-eight trials met the study inclusion criteria. Of these 11 were excluded from the analysis as they did not report AA men. A total of 5802 men participated in the remaining 47 trials. Of these, 917 (15.8%) were AA and 4885 (84.2%) were WA men. Forty (85.1%) trials used pharmaceutical medication therapies or other clinical procedures. None of the medications or clinical procedures used were indicated for treatment of obesity and T2D. 5 (10.6%) trials addressed treatment preferences, survivorship, coping, function, and incontinence among PCa patients. Only 2 (4.25%) trials examined weight loss and diet. Conclusions None of the completed federally funded PCa clinical trials that included AA men used methods to control T2D. Only an insignificant number (4.25%) attempted to control obesity. This gap in therapeutic optimization to control these comorbid conditions indicates a critical area in need of federal funding priority.